New immune drug tested in patients who have run out of options
Disease control
Ongoing
This is a very early, first-in-human study to test the safety of a new drug called ADG206. It is enrolling 14 people with advanced or metastatic solid tumors that have progressed after all standard treatments. The main goal is to find a safe dose and see how the body handles the …
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC